2022 General Investor Relations Presentation
A research-driven innovation process
Supported by unrivalled capabilities and innovation
> 69
Creation and
application
Centres
-0000
>>120,000
CHF 562 mln
Products sold
per year
R&D spend in 2021,
8.4% of sales
> 550
Employees in
Science &
Technology
> 3,600
Active
patents
Innovation initiatives and priorities
Supplier enabled
innovation
partnerships with
bioscience companies
Delivering differentiating
technologies and solutions in
Flavours, nutritional and
functional ingredients (clean
label delivery systems, health
and wellbeing solutions etc.)
Enabling novel consumer
experiences in Fragrances:
naturals, new sensory
experiences, sustainable
new molecules and
precursors etc.
Givaudan
2022 General Investor Relations presentation
February 2022
10View entire presentation